Razi Ghori

4.5k total citations
27 papers, 953 citations indexed

About

Razi Ghori is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Razi Ghori has authored 27 papers receiving a total of 953 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Razi Ghori's work include Cancer Immunotherapy and Biomarkers (14 papers), Melanoma and MAPK Pathways (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Razi Ghori is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Melanoma and MAPK Pathways (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Razi Ghori collaborates with scholars based in United States, Australia and Spain. Razi Ghori's co-authors include Georgina V. Long, Antoni Ribas, Victoria Atkinson, Bijoyesh Mookerjee, Nageatte Ibrahim, Blanca Homet Moreno, Rosalie Fisher, Michele Del Vecchio, Pier Francesco Ferrucci and Paolo A. Ascierto and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Razi Ghori

27 papers receiving 942 citations

Peers

Razi Ghori
Comparison fields: 5 of 58
  • Oncology 763
  • Molecular Biology 400
  • Immunology 234
  • Pulmonary and Respiratory Medicine 167
  • Pathology and Forensic Medicine 165
Replace Jennifer E. Howes with:
Jennifer E. Howes United States
Mark Gimbel United States
Rebecca Hong United States
Meredith McKean United States
Jorge Chaves United States
Timothy Larson United States
Karen A. Cadoo United States
Hirokazu Ogino Japan
Navid Hafez United States
Matthew Dankner Canada
Jennifer E. Howes United States View profile →
Citations per field, relative to Razi Ghori
Razi Ghori · 1×
Citations per year, relative to Razi Ghori
Razi Ghori · 1×

Countries citing papers authored by Razi Ghori

Since Specialization
Citations

This map shows the geographic impact of Razi Ghori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Razi Ghori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Razi Ghori more than expected).

Fields of papers citing papers by Razi Ghori

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Razi Ghori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Razi Ghori. The network helps show where Razi Ghori may publish in the future.

Co-authorship network of co-authors of Razi Ghori

This figure shows the co-authorship network connecting the top 25 collaborators of Razi Ghori. A scholar is included among the top collaborators of Razi Ghori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Razi Ghori. Razi Ghori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP‐005 study recurrent glioblastoma cohort
2025 ·Cancer ·Sun Young Rha, Eduardo Castañón, Sanjeev Gill, Hélène Senellart, Juanita Lopez, Iván Márquez‐Rodas, Iván Victoria, Tae Min Kim, Zarnie Lwin, Michael C. Burger, Matteo Simonelli, Philippe A. Cassier, Andrew Hendifar, (unknown), Corina E. Dutcus, Chinyere E. Okpara, Razi Ghori, Fan Jin, Roman Groisberg, Luis J. Villanueva-Rivera
1
2
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study
2024 ·Cancer ·Hyun Cheol Chung, Esma Saâda-Bouzid, Federico Longo, Eduardo Yáñez, Seock‐Ah Im, Eduardo Castañón, Danielle Desautels, Donna M. Graham, Javier García-Corbacho, Juanita Lopez, Corina E. Dutcus, Chinyere E. Okpara, Razi Ghori, Fan Jin, Roman Groisberg, (unknown)
4
3
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study
2024 ·Gynecologic Oncology ·Antonio González-Martı́n, Hyun Cheol Chung, Esma Saâda-Bouzid, Eduardo Yáñez, Hélène Senellart, Philippe A. Cassier, Bristi Basu, Bradley R. Corr, Eugenia Girda, Corina E. Dutcus, Chinyere E. Okpara, Razi Ghori, Fan Jin, Roman Groisberg, Zarnie Lwin
8
4
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma
2023 ·Cancer Discovery ·Jennifer A. Woyach, Deborah M. Stephens, Ian W. Flinn, Seema A. Bhat, Ronald E. Savage, (unknown), Sudharshan Eathiraj, Sean D. Reiff, (unknown), (unknown), (unknown), (unknown), Brian Schwartz, Razi Ghori, Mohammed Z.H. Farooqui, John C. Byrd
29
5
Updated follow‐up of BELLWAVE‐001: an open‐label, single‐arm, phase 1/2 study of the efficacy and safety of nemtabrutinib for the treatment of B‐cell malignancies
2023 ·Hematological Oncology ·Herbert Eradat, Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Danielle M. Brander, Michael Tees, Sameer A. Parikh, Tycel Phillips, Razi Ghori, Ima Paydar, Mohammed Z.H. Farooqui, John C. Byrd, Deborah M. Stephens
1
6
P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES
2023 ·HemaSphere ·Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Herbert Eradat, Danielle M. Brander, Michael Tees, Sameer A. Parikh, Tycel Phillips, Razi Ghori, Ima Paydar, Mohammed Farooqui, John C. Byrd, Deborah M. Stephens
4
7
Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
2022 ·Blood ·Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Herbert Eradat, Danielle M. Brander, Michael Tees, Sameer A. Parikh, Tycel Phillips, Razi Ghori, Nishitha Reddy, Mohammed Z.H. Farooqui, John C. Byrd, Deborah M. Stephens
30
8
Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.
2022 ·Journal of Clinical Oncology ·Antoni Ribas, Pier Francesco Ferrucci, Victoria Atkinson, (unknown), Georgina V. Long, Donald P. Lawrence, Michele Del Vecchio, Omid Hamid, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Wilson H. Miller, Matteo S. Carlino, Anna Maria Di Giacomo, Inge Marie Svane, Razi Ghori, (unknown), Scott J. Diede, Paolo A. Ascierto
6
9
P-139 A phase 2 multicohort study (LEAP-005) of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Pancreatic cancer cohort
2021 ·Annals of Oncology ·Hyun Cheol Chung, Luis J. Villanueva-Rivera, Donna M. Graham, Esma Saâda-Bouzid, Razi Ghori, Peter Kubiak, (unknown), (unknown), Carlos Gomez‐Roca
2
10
Abstract PS12-07: Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study
2021 ·Cancer Research ·Hyun Cheol Chung, Esma Saâda-Bouzid, (unknown), Eduardo Yáñez, Seock‐Ah Im, Eduardo Castañón, Donna M. Graham, Javier García-Corbacho, Juanita Lopez, Razi Ghori, Corina E. Dutcus, Alan D. Smith, Kevin Norwood, Carlos Gomez‐Roca
9
11
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.
2021 ·Journal of Clinical Oncology ·Hyun Cheol Chung, Zarnie Lwin, Carlos Gomez‐Roca, Federico Longo, Eduardo Yáñez, (unknown), Donna M. Graham, Mark Doherty, Philippe A. Cassier, Juanita Lopez, Bristi Basu, Andrew Hendifar, Corinne Maurice‐Dror, Sanjeev Gill, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Norwood, Esma Saâda-Bouzid
4
12
Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.
2021 ·Journal of Clinical Oncology ·Luis J. Villanueva-Rivera, Zarnie Lwin, Hyun Cheol Chung, Carlos Gomez‐Roca, Federico Longo, Eduardo Yáñez, Hélène Senellart, Mark Doherty, Javier García-Corbacho, Andrew Hendifar, Corinne Maurice‐Dror, Sanjeev Gill, Tae Won Kim, Daniel Heudobler, Nicolas Penel, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Norwood, Donna M. Graham
49
13
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
2020 ·Journal for ImmunoTherapy of Cancer ·Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, (unknown), Inge Marie Svane, Michal Lotem, (unknown), Eduard Gasal, Razi Ghori, Scott J. Diede, (unknown), Antoni Ribas, Paolo A. Ascierto
111
14
LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours
2020 ·Annals of Oncology ·Zarnie Lwin, Carlos Gomez‐Roca, Esma Saâda-Bouzid, (unknown), (unknown), S-A. Im, Eduardo Castañón, Hélène Senellart, Donna M. Graham, Martin H. Voss, Mark Doherty, Juanita Lopez, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Norwood, Hyun Cheol Chung
59
15
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
2019 ·Nature Medicine ·Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Anna Maria Di Giacomo, Inge Marie Svane, Michal Lotem, Gil Bar‐Sela, Félix Couture, Bijoyesh Mookerjee, Razi Ghori, Nageatte Ibrahim, Blanca Homet Moreno, Antoni Ribas
219
16
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
2019 ·Nature Medicine ·Antoni Ribas, Donald P. Lawrence, Victoria Atkinson, Sachin Agarwal, Wilson H. Miller, Matteo S. Carlino, Rosalie Fisher, Georgina V. Long, F. Stephen Hodi, Jennifer Tsoi, Catherine S. Grasso, Bijoyesh Mookerjee, Qing Zhao, Razi Ghori, Blanca Homet Moreno, Nageatte Ibrahim, Omid Hamid
230
17
KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma
2018 ·Annals of Oncology ·Paolo A. Ascierto, Pier Francesco Ferrucci, (unknown), Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Anna Maria Di Giacomo, Inge Marie Svane, Michal Lotem, Gil Bar‐Sela, Félix Couture, Bijoyesh Mookerjee, Razi Ghori, Nageatte Ibrahim, Blanca Homet Moreno, Antoni Ribas
38
18
A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.
2018 ·Journal of Clinical Oncology ·Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol Rocafiguera, Lionel Karlin, Robert M. Rifkin, Habte Yimer, Richard LeBlanc, Naoki Takezako, Robert McCroskey, Kenshi Suzuki, Michèle Cavo, Thierry Façon, Sundar Jagannath, Sagar Lonial, Razi Ghori, Mohammed Z.H. Farooqui, Jason J. Z. Liao, Patricia Marinello, Jesús F. San Miguel
18
19
KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM)
2016 ·Annals of Oncology ·Sagar Lonial, (unknown), Habte Yimer, María‐Victoria Mateos, Robert M. Rifkin, Fredrik Schjesvold, Jesús F. San Miguel, Razi Ghori, Patricia Marinello, Sundar Jagannath
2
20
Clinical Relevance of Vilazodone Treatment in Patients With Major Depressive Disorder
2014 ·The Primary Care Companion For CNS Disorders ·Larry Culpepper, Maju Mathews, Razi Ghori, John Edwards
2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer E. Howes Breakdown of academic impact, for papers by Mark Gimbel Breakdown of academic impact, for papers by Rebecca Hong Breakdown of academic impact, for papers by Meredith McKean Breakdown of academic impact, for papers by Jorge Chaves Breakdown of academic impact, for papers by Timothy Larson Breakdown of academic impact, for papers by Karen A. Cadoo Breakdown of academic impact, for papers by Hirokazu Ogino Breakdown of academic impact, for papers by Navid Hafez Breakdown of academic impact, for papers by Matthew Dankner
Rankless by CCL
2026